Viridian Therapeutics (NASDAQ: VRDN) insider transactions
In the twelve months to 10 November 2026, executives and directors of Viridian Therapeutics reported 3 open-market sales of 16,484 shares ($418,990) and 1 open-market purchase of 1,176,470 shares ($20.0m), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 19 August 2026 | Tousignant Jennifer | Chief Legal Officer | Open-market sale | −4,212 | $24.50 | 0 | Form 4 |
| 19 August 2026 | Tousignant Jennifer | Chief Legal Officer | Option exercise | +10,000 | $14.41 | 10,000 | Form 4 |
| 19 August 2026 | Tousignant Jennifer | Chief Legal Officer | Open-market sale | −10,000 | $24.50 | 0 | Form 4 |
| 14 August 2026 | Tripuraneni Radhika | Chief Medical Officer | Option exercise | +40,000 | $13.21 | 40,000 | Form 4 |
| 11 May 2026 | Fairmount Healthcare Fund II L.P. | Director | Open-market purchase | +1,176,470 | $17.00 | 5,090,928 | Form 4 |
| 3 March 2026 | Mahoney Stephen F. | President and CEO | Option exercise | +18,357 | — | 40,757 | Form 4 |
| 3 March 2026 | Mahoney Stephen F. | President and CEO | Shares withheld for tax | −7,627 | $29.32 | 33,130 | Form 4 |
| 3 March 2026 | Beetham Thomas W. | Chief Operating Officer | Option exercise | +9,409 | — | 16,409 | Form 4 |
| 3 March 2026 | Beetham Thomas W. | Chief Operating Officer | Shares withheld for tax | −3,138 | $29.32 | 13,271 | Form 4 |
| 3 March 2026 | Harmon Seth | Chief Financial Officer | Option exercise | +6,267 | — | 9,881 | Form 4 |
| 3 March 2026 | Harmon Seth | Chief Financial Officer | Shares withheld for tax | −2,091 | $29.32 | 7,790 | Form 4 |
| 3 March 2026 | Tousignant Jennifer | Chief Legal Officer | Option exercise | +5,169 | — | 5,169 | Form 4 |
| 3 March 2026 | Tousignant Jennifer | Chief Legal Officer | Shares withheld for tax | −1,724 | $29.32 | 3,445 | Form 4 |
| 31 December 2025 | Tousignant Jennifer | Chief Legal Officer | Open-market sale | −2,272 | $31.16 | 0 | Form 4 |
| 23 October 2025 | Fairmount Healthcare Fund II GP LLC | Director | Open-market purchase | +454,545 | $22.00 | 3,914,458 | Form 4 |
| 10 June 2025 | Fairmount Funds Management LLC | Director | Option exercise | +12,500 | $12.31 | 3,459,913 | Form 4 |
| 9 June 2025 | Fairmount Funds Management LLC | Director | Option exercise | +1,600 | $7.80 | 3,447,413 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Viridian Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.